Keryx Biopharmaceuticals Inc (KERX)

5.25
NASDAQ : Health Care
Prev Close 5.25
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.80 / 7.80
Avg Volume 1.74M
Exchange NASDAQ
Shares Outstanding 105.90M
Market Cap 547.48M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Keryx Biopharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of October 3, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Keryx Biopharmaceuticals, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of October 3, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Keryx Biopharmaceuticals, Inc.

KERX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Keryx Biopharmaceuticals, Inc. And A Lead Plaintiff Deadline Of October 3, 2016

KERX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Keryx Biopharmaceuticals, Inc. And A Lead Plaintiff Deadline Of October 3, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Keryx Biopharmaceuticals, Inc.

Robbins Geller Rudman & Dowd LLP Updates Investors Regarding Securities Class Action Suit Against Keryx Biopharmaceuticals, Inc. And Lead Plaintiff Opportunity

Robbins Geller Rudman & Dowd LLP Updates Investors Regarding Securities Class Action Suit Against Keryx Biopharmaceuticals, Inc. And Lead Plaintiff Opportunity

Keryx Common Stock Prices Remain Depressed Due to New Questions Raised About Viability of Investment

Brower Piven Alerts Shareholders Of Upcoming Deadline In Class Action Lawsuit And Encourages Those With Losses From Investment In Keryx Pharmaceuticals, Inc. To Contact The Firm

Brower Piven Alerts Shareholders Of Upcoming Deadline In Class Action Lawsuit And Encourages Those With Losses From Investment In Keryx Pharmaceuticals, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Keryx Biopharmaceuticals, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of October 3, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Keryx Biopharmaceuticals, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of October 3, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Keryx Biopharmaceuticals, Inc.

KERX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Keryx Biopharmaceuticals, Inc. And A Lead Plaintiff Deadline Of October 3, 2016

KERX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of Commencement Of A Class Action Involving Keryx Biopharmaceuticals, Inc. And A Lead Plaintiff Deadline Of October 3, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals Becomes Oversold (KERX)

Keryx Biopharmaceuticals Becomes Oversold (KERX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering breakout trades.

SHAREHOLDER ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors Of Important Deadline In Class Action - KERX

SHAREHOLDER ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors Of Important Deadline In Class Action - KERX

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Keryx Biopharmaceuticals, Inc.

Cohen Milstein Sellers & Toll PLLC Announces The Investigation Of Keryx Biopharmaceuticals, Inc.

Cohen Milstein Sellers & Toll PLLC Announces The Investigation Of Keryx Biopharmaceuticals, Inc.

Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Keryx Biopharmaceuticals, Inc.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Keryx Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Keryx Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

Today's Perilous Reversal Stock: Keryx Biopharmaceuticals (KERX)

Today's Perilous Reversal Stock: Keryx Biopharmaceuticals (KERX)

Trade-Ideas LLC identified Keryx Biopharmaceuticals (KERX) as a "perilous reversal" (up big yesterday but down big today) candidate

IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Keryx Biopharmaceuticals Inc. And Encourages Investors With Losses To Contact The Firm

Lundin Law PC (the "Firm") announces that a class action lawsuit has been filed against Keryx Biopharmaceuticals Inc.